Skip to content
Annalist
Companies Compare Method Data Quality For AI agents

CVS Health Corporation

CVS · NYSE · Health care, pharmacy and health services · United States · US GAAP · Fiscal year ends December

Latest report: Q2 FY2026, the quarter ended 30 June 2026, released 5 August 2026. Snapshot FY2026Q2_cbdfaab4.

Overview

Revenue, quarter
+7.3% year on year
Operating income, quarter
+97.5% year on year
Net income, quarter
+192% year on year
Diluted EPS, quarter
+189% year on year
Operating margin, last 4 quarters
−0.3pp year on year
Return on equity, last 4 quarters
+0.3pp year on year

Select a figure to see the document it came from.

Key Findings

Findings for the latest quarter, with their history over earlier quarters.

  1. Revenue for the quarter ended 30 June 2026 was US$106.1 billion, 7.3% higher than in the same quarter a year earlier.

    Strengthenedin Q2 FY2026 · stated since Q2 FY2024
    Rule: Revenue against a year earlier · Sources 10-Q 2026-06
    History of this finding, 9 records
    1. Q2 FY2026 StrengthenedRevenue for the quarter ended 30 June 2026 was US$106.1 billion, 7.3% higher than in the same quarter a year earlier.Recorded from FY2026Q2_41718c6c · data update
    2. Q1 FY2026 WeakenedRevenue for the quarter ended 31 March 2026 was US$100.4 billion, 6.2% higher than in the same quarter a year earlier.Reconstructed · data update
    3. Q4 FY2025 ConfirmedRevenue for the quarter ended 31 December 2025 was US$105.7 billion, 8.2% higher than in the same quarter a year earlier.Reconstructed · data update
    4. Q3 FY2025 ConfirmedRevenue for the quarter ended 30 September 2025 was US$102.9 billion, 7.8% higher than in the same quarter a year earlier.Reconstructed · data update
    5. Q2 FY2025 StrengthenedRevenue for the quarter ended 30 June 2025 was US$98.9 billion, 8.4% higher than in the same quarter a year earlier.Reconstructed · data update
    6. Q1 FY2025 StrengthenedRevenue for the quarter ended 31 March 2025 was US$94.6 billion, 7.0% higher than in the same quarter a year earlier.Reconstructed · data update
    7. Q4 FY2024 WeakenedRevenue for the quarter ended 31 December 2024 was US$97.7 billion, 4.2% higher than in the same quarter a year earlier.Reconstructed · data update
    8. Q3 FY2024 StrengthenedRevenue for the quarter ended 30 September 2024 was US$95.4 billion, 6.3% higher than in the same quarter a year earlier.Reconstructed · data update
    9. Q2 FY2024 NewRevenue for the quarter ended 30 June 2024 was US$91.2 billion, 2.6% higher than in the same quarter a year earlier.Reconstructed · initial
  2. Net income attributable to the company was US$3.0 billion, 191.8% higher than in the same quarter a year earlier.

    Strengthenedin Q2 FY2026 · stated since Q4 FY2025
    Rule: Net income against a year earlier · Sources 10-Q 2026-06
    History of this finding, 13 records
    1. Q2 FY2026 StrengthenedNet income attributable to the company was US$3.0 billion, 191.8% higher than in the same quarter a year earlier.Recorded from FY2026Q2_41718c6c · data update
    2. Q1 FY2026 WeakenedNet income attributable to the company was US$2.9 billion, 65.4% higher than in the same quarter a year earlier.Reconstructed · data update
    3. Q4 FY2025 NewNet income attributable to the company was US$2.9 billion, 79.0% higher than in the same quarter a year earlier.Reconstructed · data update
    4. Q4 FY2025 RetiredThe finding changed to higher than a year earlier.Reconstructed · data update
    5. Q3 FY2025 NewThe company reported a net loss of US$4.0 billion, against net income of US$87 million in the same quarter a year earlier.Reconstructed · data update
    6. Q3 FY2025 RetiredThe finding changed to a loss.Reconstructed · data update
    7. Q2 FY2025 NewNet income attributable to the company was US$1.0 billion, 42.3% lower than in the same quarter a year earlier.Reconstructed · data update
    8. Q2 FY2025 RetiredThe finding changed to lower than a year earlier.Reconstructed · data update
    9. Q1 FY2025 NewNet income attributable to the company was US$1.8 billion, 59.8% higher than in the same quarter a year earlier.Reconstructed · data update
    10. Q1 FY2025 RetiredThe finding changed to higher than a year earlier.Reconstructed · data update
    11. Q4 FY2024 WeakenedNet income attributable to the company was US$1.6 billion, 19.6% lower than in the same quarter a year earlier.Reconstructed · data update
    12. Q3 FY2024 StrengthenedNet income attributable to the company was US$87 million, 96.2% lower than in the same quarter a year earlier.Reconstructed · data update
    13. Q2 FY2024 NewNet income attributable to the company was US$1.8 billion, 6.9% lower than in the same quarter a year earlier.Reconstructed · initial
  3. The operating margin over the last 4 quarters was 2.0%, 0.3 percentage points lower than a year earlier.

    Confirmedin Q2 FY2026 · stated since Q3 FY2024
    Rule: Operating margin against a year earlier · Sources 10-Q 2025-09, 10-K 2025-12, 10-Q 2026-03 and 1 more
    History of this finding, 11 records
    1. Q2 FY2026 ConfirmedThe operating margin over the last 4 quarters was 2.0%, 0.3 percentage points lower than a year earlier.Recorded from FY2026Q2_41718c6c · wording
    2. Q2 FY2026 WeakenedThe operating margin over the last four quarters was 2.0%, 0.3 percentage points lower than a year earlier.Recorded from FY2026Q2_41718c6c · data update
    3. Q1 FY2026 ConfirmedThe operating margin over the last four quarters was 1.5%, 1.1 percentage points lower than a year earlier.Reconstructed · data update
    4. Q4 FY2025 WeakenedThe operating margin over the last four quarters was 1.2%, 1.1 percentage points lower than a year earlier.Reconstructed · data update
    5. Q3 FY2025 StrengthenedThe operating margin over the last four quarters was 1.2%, 1.3 percentage points lower than a year earlier.Reconstructed · data update
    6. Q2 FY2025 ConfirmedThe operating margin over the last four quarters was 2.3%, 1.1 percentage points lower than a year earlier.Reconstructed · data update
    7. Q1 FY2025 WeakenedThe operating margin over the last four quarters was 2.5%, 0.9 percentage points lower than a year earlier.Reconstructed · data update
    8. Q4 FY2024 ConfirmedThe operating margin over the last four quarters was 2.3%, 1.6 percentage points lower than a year earlier.Reconstructed · data update
    9. Q3 FY2024 NewThe operating margin over the last four quarters was 2.6%, 1.5 percentage points lower than a year earlier.Reconstructed · data update
    10. Q3 FY2024 RetiredThe finding changed to lower than a year earlier.Reconstructed · data update
    11. Q2 FY2024 NewThe operating margin over the last four quarters was 3.4%, 1.5 percentage points higher than a year earlier.Reconstructed · initial
  4. Return on equity over the last 4 quarters was 6.2%, against 5.9% a year earlier.

    Confirmedin Q2 FY2026 · first stated
    Rule: Return on equity against a year earlier · Sources 10-Q 2025-06, 10-Q 2026-06, 10-Q 2025-09 and 3 more
    History of this finding, 12 records
    1. Q2 FY2026 ConfirmedReturn on equity over the last 4 quarters was 6.2%, against 5.9% a year earlier.Recorded from FY2026Q2_41718c6c · wording
    2. Q2 FY2026 NewReturn on equity over the last four quarters was 6.2%, against 5.9% a year earlier.Recorded from FY2026Q2_41718c6c · data update
    3. Q2 FY2026 RetiredThe finding changed to higher than a year earlier.Recorded from FY2026Q2_41718c6c · data update
    4. Q1 FY2026 WeakenedReturn on equity over the last four quarters was 3.8%, against 7.0% a year earlier.Reconstructed · data update
    5. Q4 FY2025 WeakenedReturn on equity over the last four quarters was 2.3%, against 6.1% a year earlier.Reconstructed · data update
    6. Q3 FY2025 StrengthenedReturn on equity over the last four quarters was 0.6%, against 6.7% a year earlier.Reconstructed · data update
    7. Q2 FY2025 StrengthenedReturn on equity over the last four quarters was 5.9%, against 9.7% a year earlier.Reconstructed · data update
    8. Q1 FY2025 WeakenedReturn on equity over the last four quarters was 7.0%, against 10.1% a year earlier.Reconstructed · data update
    9. Q4 FY2024 ConfirmedReturn on equity over the last four quarters was 6.1%, against 11.3% a year earlier.Reconstructed · data update
    10. Q3 FY2024 NewReturn on equity over the last four quarters was 6.7%, against 11.9% a year earlier.Reconstructed · data update
    11. Q3 FY2024 RetiredThe finding changed to lower than a year earlier.Reconstructed · data update
    12. Q2 FY2024 NewReturn on equity over the last four quarters was 9.7%, against 4.0% a year earlier.Reconstructed · initial
  5. Free cash flow over the last 4 quarters was US$11.8 billion, and operating cash flow was 3.0 times net income attributable to the company.

    Interpretation. Operating cash flow paid for all capital expenditure, and the rest is free for dividends, share buybacks or debt repayment.

    Confirmedin Q2 FY2026 · stated since Q2 FY2024
    Rule: Free cash flow · Sources 10-Q 2025-06, 10-Q 2025-09, 10-K 2025-12 and 2 more
    History of this finding, 10 records
    1. Q2 FY2026 ConfirmedFree cash flow over the last 4 quarters was US$11.8 billion, and operating cash flow was 3.0 times net income attributable to the company.Recorded from FY2026Q2_41718c6c · wording
    2. Q2 FY2026 StrengthenedFree cash flow over the last four quarters was US$11.8 billion, and operating cash flow was 3.0 times net income attributable to the company.Recorded from FY2026Q2_41718c6c · data update
    3. Q1 FY2026 WeakenedFree cash flow over the last four quarters was US$7.4 billion, and operating cash flow was 3.5 times net income attributable to the company.Reconstructed · data update
    4. Q4 FY2025 StrengthenedFree cash flow over the last four quarters was US$7.8 billion, and operating cash flow was 6.0 times net income attributable to the company.Reconstructed · data update
    5. Q3 FY2025 StrengthenedFree cash flow over the last four quarters was US$6.3 billion, and operating cash flow was 19.4 times net income attributable to the company.Reconstructed · data update
    6. Q2 FY2025 WeakenedFree cash flow over the last four quarters was US$4.8 billion, and operating cash flow was 1.7 times net income attributable to the company.Reconstructed · data update
    7. Q1 FY2025 WeakenedFree cash flow over the last four quarters was US$5.9 billion, and operating cash flow was 1.7 times net income attributable to the company.Reconstructed · data update
    8. Q4 FY2024 StrengthenedFree cash flow over the last four quarters was US$6.3 billion, and operating cash flow was 2.0 times net income attributable to the company.Reconstructed · data update
    9. Q3 FY2024 WeakenedFree cash flow over the last four quarters was US$1.7 billion, and operating cash flow was 0.9 times net income attributable to the company.Reconstructed · data update
    10. Q2 FY2024 NewFree cash flow over the last four quarters was US$5.3 billion, and operating cash flow was 1.1 times net income attributable to the company.Reconstructed · initial
  6. Net debt was US$47.5 billion at 30 June 2026, 3.7 times EBITDA over the last 4 quarters.

    Confirmedin Q2 FY2026 · stated since Q2 FY2024
    Rule: Net debt or net cash · Sources 10-Q 2026-06, 10-Q 2025-09, 10-K 2025-12 and 1 more
    History of this finding, 10 records
    1. Q2 FY2026 ConfirmedNet debt was US$47.5 billion at 30 June 2026, 3.7 times EBITDA over the last 4 quarters.Recorded from FY2026Q2_41718c6c · wording
    2. Q2 FY2026 WeakenedNet debt was US$47.5 billion at 30 June 2026, 3.7 times EBITDA over the last four quarters.Recorded from FY2026Q2_41718c6c · data update
    3. Q1 FY2026 ConfirmedNet debt was US$51.3 billion at 31 March 2026, 4.9 times EBITDA over the last four quarters.Reconstructed · data update
    4. Q4 FY2025 ConfirmedNet debt was US$54.0 billion at 31 December 2025, 5.8 times EBITDA over the last four quarters.Reconstructed · data update
    5. Q3 FY2025 ConfirmedNet debt was US$54.6 billion at 30 September 2025, 5.7 times EBITDA over the last four quarters.Reconstructed · data update
    6. Q2 FY2025 ConfirmedNet debt was US$52.3 billion at 30 June 2025, 3.9 times EBITDA over the last four quarters.Reconstructed · data update
    7. Q1 FY2025 WeakenedNet debt was US$52.1 billion at 31 March 2025, 3.7 times EBITDA over the last four quarters.Reconstructed · data update
    8. Q4 FY2024 ConfirmedNet debt was US$55.3 billion at 31 December 2024, 4.2 times EBITDA over the last four quarters.Reconstructed · data update
    9. Q3 FY2024 StrengthenedNet debt was US$55.9 billion at 30 September 2024, 4.0 times EBITDA over the last four quarters.Reconstructed · data update
    10. Q2 FY2024 NewNet debt was US$50.1 billion at 30 June 2024, 3.0 times EBITDA over the last four quarters.Reconstructed · initial

Records before Q2 FY2026 are reconstructed from the latest snapshot. Ledger: findings.json. Correction of 20 October 2026: The fourth quarter of 2021 of CVS Health came from a fiscal year and 9 months of different filings; it now comes from one set of filings, with operating income of US$2.23 billion where US$2.35 billion was published. 5 quarterly repurchases of shares that came out negative from revised cumulative figures are withheld. Dividends per share of 3 fourth quarters are no longer published: 2 derived from the figures of 2 filings and 1 that the set of filings of its quarter does not report. No finding cites the figures. Correction of 22 October 2026: Changes against a year earlier compared 2 figures of different bases where a stock split, a spin-off or a restatement came between the 2 periods. 14 growth values changed, among them net income growth for fiscal 2021, 11.5% before the correction and 10.2% on one basis. No finding states the changes concerned.

Credit, liquidity, earnings quality and score findings: Analysis.

Data

Source documents26 documents, latest Form 10-Q, period ended 30 June 2026List
DownloadsExcel workbook · JSON
SnapshotFY2026Q2_cbdfaab4

Corporate Events

  1. Acquisitions paid in cash31 December 2023

    Paid US$16.6 billion in cash for business acquisitions in fiscal 2023, 7.3% of total assets at the start of the year.

    Source 10-K 2025-12

Earnings, Returns and Balance Sheet

Revenue

By quarter, US dollars

Operating Income

By quarter, US dollars

Net Income Attributable to the Company

By quarter, US dollars

Margins

Last 4 quarters at each quarter end, per cent

Returns

Last 4 quarters, per cent

Free Cash Flow

Operating cash flow less capital expenditure, by quarter, US dollars

Net Debt

Total debt less cash and short-term investments, at quarter end, US dollars

Diluted Earnings per Share

By quarter, as reported

Financial Statements

Figures as filed. Select a figure for its source document and method; a small d marks a quarter derived from cumulative reports.

The statements are loading. They are also available as JSON and CSV.

Ratios

Select a ratio for its formula and the figures it uses, each with its document; (i) gives its definition.

The ratios are loading.

Source Documents

Documents of this snapshot, latest first.

DocumentDateId
Form 10-Q, period ended 30 June 20265 Aug 202610-Q:0000064803-26-000098
Form 10-Q, period ended 31 March 20266 May 202610-Q:0000064803-26-000052
Form 10-K, period ended 31 December 202510 Feb 202610-K:0000064803-26-000010
Form 10-Q, period ended 30 September 202529 Oct 202510-Q:0000064803-25-000037
Form 10-Q, period ended 30 June 202531 Jul 202510-Q:0000064803-25-000024
Form 10-Q, period ended 31 March 20251 May 202510-Q:0000064803-25-000013
Form 10-K, period ended 31 December 202412 Feb 202510-K:0000064803-25-000007
Form 10-Q, period ended 30 September 20246 Nov 202410-Q:0000064803-24-000034
Form 10-Q, period ended 30 June 20247 Aug 202410-Q:0000064803-24-000029
Form 10-Q, period ended 31 March 20241 May 202410-Q:0000064803-24-000016
Form 10-K, period ended 31 December 20237 Feb 202410-K:0000064803-24-000007
Form 10-Q, period ended 30 September 20231 Nov 202310-Q:0000064803-23-000047
Form 10-Q, period ended 30 June 20232 Aug 202310-Q:0000064803-23-000033
Form 10-Q, period ended 31 March 20233 May 202310-Q:0000064803-23-000016
Form 10-K, period ended 31 December 20228 Feb 202310-K:0000064803-23-000009
Form 10-Q, period ended 30 September 20222 Nov 202210-Q:0000064803-22-000038
Form 10-Q, period ended 30 June 20223 Aug 202210-Q:0000064803-22-000029
Form 10-Q, period ended 31 March 20224 May 202210-Q:0000064803-22-000016
Form 10-K, period ended 31 December 20219 Feb 202210-K:0000064803-22-000008
Form 10-Q, period ended 30 September 20213 Nov 202110-Q:0000064803-21-000034
Form 10-Q, period ended 30 June 20214 Aug 202110-Q:0000064803-21-000028
Form 10-Q, period ended 31 March 20214 May 202110-Q:0000064803-21-000017
Form 10-K, period ended 31 December 202016 Feb 202110-K:0000064803-21-000011
Form 10-Q, period ended 30 September 20206 Nov 202010-Q:0000064803-20-000041
Form 10-Q, period ended 30 June 20205 Aug 202010-Q:0000064803-20-000030
Form 10-Q, period ended 31 March 20206 May 202010-Q:0000064803-20-000015

Checks

297285 of 297 checks passed, 12 warnings
Fiscal calendar68 passedFiscal years last 350 to 380 days, quarters 80 to 125 days, and each period starts on the day after the one before. Checked at error level.
Quarters and fiscal year131 of 138 passedThe 4 quarters of every item add up to its fiscal year, or a later filing restated the year. Checked at error level; a difference that a later report explains is a warning, which does not stop publication.
Operating income, FY2021: $13,193m against $13,310m
Income before income taxes, FY2021: $10,420m against $10,537m
Income tax expense, FY2021: $2,522m against $2,548m
Net income including noncontrolling interests, FY2021: $7,898m against $7,989m
Net income attributable to the company, FY2021: $7,910m against $8,001m
Depreciation and amortisation, FY2021: $4,512m against $4,486m
Withheld values5 values withheldA value that contradicts the definition of its item, or that documents report in contradiction, is withheld. Checked at warning level.
Repurchases of common stock, Q2 FY2023: withheld, negative where the item cannot be negative
Repurchases of common stock, Q3 FY2023: withheld, negative where the item cannot be negative
Repurchases of common stock, Q4 FY2023: withheld, negative where the item cannot be negative
Repurchases of common stock, Q2 FY2024: withheld, negative where the item cannot be negative
Repurchases of common stock, Q3 FY2024: withheld, negative where the item cannot be negative
Filer identity1 passedThe documents are those of the company of this page. Checked at error level.
Balance sheet identity26 passedTotal assets equal total liabilities and equity at each balance sheet date. Checked at error level.
Balance sheet structure26 passedTotal assets equal liabilities, temporary equity and total equity. Checked at warning level.
Lease liabilities6 passedLease payments due, less imputed interest, equal the lease liabilities. Checked at warning level.
Debt maturities6 passedThe debt maturity schedule adds up to the long-term debt. Checked at warning level.
Quarters and 9 months15 passedThe 3 reported quarters of a fiscal year add up to the reported 9-month figure. Checked at error level.
Earnings per share6 passedNet income divided by average shares agrees with reported basic earnings per share. Checked at warning level.

Data Quality

How many values of this snapshot the checks prove, and how many Annalist derives, withholds and tracks as restated. Every company.

Values published1,601
Proven by a check47.8%, 765 values
Confirmed by a second document0.0%, 0 values
Derived from reported figures19.4%, 310 values
Values withheld5
Restated figures tracked72
Changes compared on one basis19
Company lines mapped0 of 1 reviewed

Citation

Annalist, CVS Health Corporation, snapshot cvs-health/FY2026Q2_cbdfaab4 (as of FY2026 Q2); <item label>, <period>; source <document id> (<document url>)

Snapshot FY2026Q2_cbdfaab4 · dataset SHA-256 cbdfaab4f3119af0b1d0cf56ce9c3864a925c66229339a5b760e14bf252c1b51 · findings rules 0.4

Data: info.json · dataset.json · validation.json · documents.json